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Letter	  to	  the	  Editor:	  
The	  JAK	  1	  and	  2	  inhibitor	  ruxolitinib	  is	  the	  first	  drug	  licensed	  for	  the	  treatment	  of	  myelofibrosis	  and	  
has	  transformed	  the	  management	  of	  this	  condition1,2.	  	  Pulmonary	  hypertension	  is	  a	  known	  
complication	  of	  myelofibrosis3,	  but	  no	  link	  with	  ruxolitinib	  has	  previously	  been	  described.	  	  Here	  we	  
report	  for	  the	  first	  time	  an	  association	  between	  worsening	  pulmonary	  arterial	  hypertension	  (PAH)	  
and	  ruxolitinib,	  with	  improvement	  on	  withdrawal	  of	  the	  drug	  on	  two	  separate	  occasions.	  	  An	  
association	  between	  PAH	  and	  a	  number	  of	  drugs	  is	  recognised4	  and	  its	  development	  results	  in	  
considerable	  morbidity	  primarily	  due	  to	  breathlessness	  and	  reduced	  exercise	  tolerance.	  	  Symptoms	  
may	  improve	  on	  withdrawal	  of	  the	  offending	  drug,	  but	  some	  patients	  will	  have	  persistent	  symptoms	  
that	  require	  specific	  PAH	  drug	  treatment.	  	  Tyrosine	  kinase	  inhibitors	  (TKIs)	  are	  a	  diverse	  group	  of	  
drugs,	  some	  of	  which	  are	  known	  to	  affect	  the	  pulmonary	  vasculature,	  and	  while	  some	  can	  induce	  
PAH,	  others	  can	  improve	  pulmonary	  haemodynamics4,5.	  	  The	  JAK	  proteins	  are	  tyrosine	  kinase	  
proteins	  whose	  role	  in	  PAH	  is	  unclear.	  	  	  
	  
A	  57	  year	  old	  woman	  with	  a	  background	  of	  Budd-­‐Chiari	  and	  portacaval	  shunt	  in	  the	  1980s,	  testing	  
positive	  for	  the	  JAK2V617F	  mutation,	  was	  entered	  into	  a	  treatment	  trial	  for	  progressive	  
myelofibrosis	  (NCT01433445	  Phase	  1b	  –	  panobinostat	  10mg	  3	  times	  a	  week	  on	  alternate	  weeks	  and	  
ruxolitinib	  10mg	  twice	  daily).	  	  Pulmonary	  arterial	  pressures	  were	  mildly	  elevated	  on	  pre-­‐treatment	  
echocardiogram	  and	  right	  ventricle	  (RV)	  size	  and	  function	  were	  normal	  [Table	  1].	  	  Her	  itching	  and	  
splenomegaly	  improved,	  but	  after	  two	  weeks	  treatment	  she	  developed	  breathlessness	  not	  caused	  
by	  anaemia.	  	  This	  continued	  to	  progress	  and	  by	  six	  weeks	  she	  was	  also	  hypoxaemic.	  	  An	  
echocardiogram	  showed	  severe	  elevation	  of	  her	  PAP	  with	  severe	  RV	  dilatation	  and	  moderate	  
dysfunction	  [Table	  1].	  	  A	  subsequent	  right	  heart	  catheter	  demonstrated	  severe	  pre-­‐capillary	  
pulmonary	  hypertension	  (PH)	  [Table	  1].	  	  Lung	  function	  tests	  showed	  mildly	  reduced	  gas	  transfer,	  
while	  CT	  pulmonary	  angiogram	  and	  ventilation-­‐perfusion	  scans	  were	  negative	  for	  pulmonary	  
embolism.	  	  The	  panobinostat	  and	  ruxolitinib	  were	  stopped.	  	  	  
	  
Three	  months	  later	  she	  was	  WHO	  functional	  class	  III	  with	  a	  six-­‐minute	  walk	  distance	  (6MWD)	  of	  
420m.	  	  Her	  echocardiogram	  had	  improved	  with	  reduced	  pulmonary	  arterial	  pressures,	  reduced	  RV	  
dilatation	  and	  RV	  function	  was	  now	  normal	  [Table	  1].	  Her	  breathlessness	  was	  also	  improving	  and	  so	  
PAH-­‐specific	  therapy	  was	  not	  prescribed.	  	  By	  eight	  months	  her	  symptoms	  had	  returned	  to	  pre-­‐
treatment	  levels	  and	  she	  was	  WHO	  functional	  class	  II	  with	  a	  6MWD	  of	  480m.	  	  She	  was	  also	  able	  to	  
play	  badminton	  again.	  	  A	  repeat	  RHC	  demonstrated	  improved	  pulmonary	  vascular	  resistance	  and	  
improved	  cardiac	  output	  9	  months	  after	  stopping	  the	  panobinostat	  and	  ruxolitinib.	  	  However,	  she	  
wanted	  further	  therapy	  for	  worsening	  itching	  and	  splenomegaly.	  	  It	  was	  not	  clear	  which	  drug	  had	  
been	  responsible,	  but	  her	  pharmacokinetic	  studies	  showed	  serum	  panobinostat	  levels	  significantly	  
above	  the	  rest	  of	  the	  dosing	  cohort,	  possibly	  due	  to	  her	  portacaval	  shunt,	  while	  ruxolitinib	  levels	  
were	  normal.	  	  Half-­‐dose	  ruxolitinib	  was	  thus	  restarted	  under	  close	  observation	  and	  the	  patient	  was	  
provided	  with	  clear	  warning	  that	  she	  may	  develop	  worsening	  PAH	  again.	  	  	  
	  
After	  one	  month	  her	  itching	  and	  splenomegaly	  had	  improved	  without	  increasing	  breathlessness.	  	  
Though	  her	  exercise	  capacity	  on	  cardio-­‐pulmonary	  exercise	  testing	  (CPET)	  had	  reduced,	  her	  right	  
heart	  catheter	  findings	  were	  acceptable	  [Table	  1],	  so	  the	  dose	  was	  increased.	  	  After	  six	  weeks	  she	  
was	  markedly	  breathless	  on	  exertion	  again.	  	  Repeat	  CPET	  was	  consistent	  with	  worsening	  PAH	  and	  
the	  ruxolitinib	  was	  stopped.	  	  
	  
Four	  months	  later	  her	  breathlessness,	  echocardiogram	  and	  CPET	  had	  returned	  to	  baseline	  [Table	  1].	  
Unfortunately	  her	  myelofibrosis	  symptoms	  have	  deteriorated	  and	  other	  therapies	  are	  being	  
considered.	  
	  
Until	  recently,	  myelofibrosis	  treatment	  was	  limited	  to	  allogenic	  stem	  cell	  transplant	  or	  palliation.	  	  
Aberrant	  JAK/STAT	  signalling	  plays	  a	  key	  role	  in	  its	  pathogenesis6,	  particularly	  JAK1	  and	  2	  
dysregulation7.	  	  The	  novel	  drug	  ruxolitinib	  inhibits	  JAK1	  and	  2,	  improving	  splenomegaly,	  disease	  
related	  symptoms,	  quality	  of	  life	  and	  survival1,2.	  	  
	  
JAK/STAT	  signalling	  may	  be	  important	  in	  PAH	  as	  STAT3	  activation	  causes	  upregulation	  of	  mediators	  
that	  lead	  to	  proliferation	  and	  anti-­‐apoptosis	  of	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC)8.	  	  
JAK	  proteins	  cause	  STAT	  activation,	  but	  the	  role	  of	  JAK	  activation	  in	  PAH	  is	  undetermined.	  	  Though	  in	  
idiopathic	  PAH	  (IPAH),	  JAK2	  inhibition	  reduces	  proliferation	  of	  pulmonary	  arterial	  endothelial	  cells9,	  
JAK2	  upregulation	  in	  PASMC	  has	  not	  been	  demonstrated10.	  	  Also,	  JAK2	  gene	  expression	  is	  increased	  
in	  PAH	  in	  limited	  cutaneous	  sclerosis,	  but	  not	  in	  IPAH11.	  	  JAK	  inhibition	  can	  also	  initiate	  
compensatory	  pathways	  such	  as	  Src	  in	  other	  diseases	  such	  as	  non-­‐small	  cell	  lung	  cancer8,	  so	  a	  
paradoxical	  increase	  in	  STAT3	  activity	  could	  occur.	  	  In	  addition	  JAK1	  and	  2	  are	  tyrosine	  kinase	  
proteins12,	  and	  TKIs	  can	  have	  contrasting	  effects	  in	  PAH,	  with	  dasatinib	  potentially	  causing	  PAH4,	  
while	  imatinib	  improves	  pulmonary	  haemodynamics	  and	  exercise	  capacity	  in	  IPAH5.	  	  The	  potential	  
effect	  of	  JAK	  inhibition	  in	  vivo	  is	  thus	  unclear	  in	  PAH.	  	  
	  
PH	  occurs	  in	  a	  third	  of	  myelofibrosis	  patients3	  and	  in	  2-­‐6%	  of	  portal	  hypertension	  patients4.	  	  While	  
either	  could	  explain	  the	  mild	  elevation	  of	  pulmonary	  arterial	  pressures	  pre-­‐treatment	  and	  the	  
possibility	  of	  some	  residual	  PH	  after	  withdrawal,	  the	  temporal	  relationship	  with	  the	  trial	  drugs	  
makes	  progression	  of	  pre-­‐existing	  disease	  unlikely.	  	  The	  patient	  was	  not	  re-­‐challenged	  with	  
panobinostat	  on	  the	  second	  occasion	  and	  other	  histone	  deacetylase	  inhibitors	  reduce	  PAH	  in	  animal	  
models13	  implicating	  ruxolitinib	  as	  the	  cause.	  	  Ruxolitinib	  may	  improve	  PH	  in	  myelofibrosis	  based	  on	  
echocardiogram	  findings	  and	  serum	  BNP	  levels14	  but	  this	  has	  not	  been	  confirmed	  by	  right	  heart	  
catheter,	  CPET	  or	  formal	  assessment	  of	  effects	  upon	  breathlessness.	  	  The	  lack	  of	  invasive	  
haemodynamic	  data	  prior	  to	  initiation	  of	  ruxolitinib	  is	  a	  limitation	  of	  this	  case,	  but	  a	  right	  heart	  
catheter	  was	  not	  performed	  as	  the	  patient	  was	  asymptomatic	  and	  no	  prior	  link	  between	  ruxolitinib	  
and	  PAH	  had	  been	  described.	  	  However,	  PAH	  was	  confirmed	  on	  subsequent	  invasive	  testing,	  and	  
pulmonary	  vascular	  resistance	  improved	  after	  ruxolitinib	  was	  stopped.	  	  This	  correlated	  with	  both	  
improvements	  on	  echocardiogram	  and	  the	  patient’s	  symptoms.	  	  The	  patient	  then	  became	  
symptomatic	  on	  a	  second	  occasion	  when	  ruxolitinib	  was	  used	  at	  full	  dose	  with	  CPET	  evidence	  of	  
worsening	  PAH	  suggesting	  this	  drug	  was	  the	  cause.	  	  	  
	  
The	  aetiology	  of	  PH	  in	  myelofibrosis	  is	  complex15,	  but	  include	  mechanisms	  that	  augment	  venous	  
thrombosis	  and	  mechanisms	  resulting	  in	  PAH-­‐like	  disease	  such	  as	  extramedullary	  haemopoiesis.	  	  
While	  these	  may	  respond	  differently	  to	  ruxolitinib,	  our	  patient	  had	  no	  evidence	  of	  pulmonary	  
embolism,	  and	  ruxolitinib	  reduces	  extramedullary	  haematopoesis.	  	  How	  ruxolitinib	  may	  exacerbate	  
PAH	  is	  thus	  unclear.	  	  We	  recommend	  comprehensive	  and	  cautious	  monitoring	  of	  patients	  with	  
known	  PAH	  who	  are	  to	  be	  treated	  with	  ruxolitinib.	  
	  
To	  our	  knowledge	  this	  is	  the	  first	  case	  of	  PAH	  due	  to	  a	  drug	  affecting	  JAK/STAT	  signalling,	  specifically	  
a	  JAK1	  and	  2	  inhibitor.	  	  The	  mechanism	  is	  unclear,	  however	  resolution	  was	  achieved	  by	  withdrawing	  
the	  offending	  drug	  and	  PAH-­‐specific	  therapy	  was	  not	  required.	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Table	  1.	  Echocardiogram,	  right	  heart	  catheter	  and	  cardiopulmonary	  exercise	  test	  data	  obtained	  in	  relation	  to	  treatment	  received	  
for	  myelofibrosis.	  
	   First	  Treatment	  Regimen	   Second	  Treatment	  Regimen	  




































Ruxolitinib	  (mg	  BD)	  	   -­‐	   10	  	   -­‐	   -­‐	   -­‐	   5	   10	   -­‐	  
Panobinostat	  (mga)	   -­‐	   10	  	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	  
Echocardiogram	   	   	   	   	   	   	   	   	  
TR	  max	  velocity	  (m/s)	   3.2	   4.5	   …	   3.8	   …	   4.0	   …	   3.4	  
Peak	  PAP	  (mmHg)	   43	   89	   …	   65	   …	   68	   …	   51	  
TAPSE	  (mm)	   27	   27	   …	   28	   …	   26	   …	   24	  
RV	  size	   Normal	   Severe	  
dilatation	  
	   Mod	  
dilatation	  
	   Mild	  
dilatation	  
	   Mild	  
dilatation	  
RV	  function	   Normal	  	   Mod	  
impaired	  
	   Normal	   	   Mild	  
impaired	  
	   Normal	  
Right	  Heart	  Catheter	   	   	   	   	   	   	   	   	  
RAP	  (mmHg)	   …	   …	   6	   …	   5	   6	   …	   …	  
mPAP	  (mmHg)	   …	   …	   42	   …	   46	   43	   …	   …	  
PVR	  (WU)	   …	   …	   8.2	   …	   6.3	   6.0	   …	   …	  
PCWP	  (mmHg)	   …	   …	   12	   …	   10	   9	   …	   …	  
CI	  (L/min/m2)	   …	   …	   2.3	   …	   3.3	   3.4	   …	   …	  
CPET	   	   	   	   	   	   	   	   	  
VO2	  peak	  (ml/min/kg)	  
(%	  predicted)	  








VE/VCO2	  	   …	   …	   …	   …	   36.1	   38.6	   45.8	   38.1	  
AT	  (ml/min/kg)	  	   …	   …	   …	   …	   14.5	  	   12.1	  	   10.0	  	   14.3	  
Oxygen	  saturation	  (%)	   …	   …	   …	   …	   95	  to	  89	   98	  to	  89	   98	  to	  90	   96	  to	  90	  
aPanobinostat	  dosage	  –	  10mg	  3	  times	  a	  week	  on	  alternate	  weeks	  
AT	  =	  anaerobic	  threshold;	  BD	  =	  twice	  daily;	  CI	  =	  cardiac	  index;	  mPAP	  =	  mean	  pulmonary	  arterial	  pressure;	  PAP	  =	  pulmonary	  
arterial	  pressure;	  PCWP	  =	  pulmonary	  capillary	  wedge	  pressure;	  PVR	  =	  pulmonary	  vascular	  resistance;	  RAP	  =	  right	  atrial	  pressure;	  
TAPSE	  =	  tricuspid	  annular	  plane	  systolic	  excursion;	  TR	  =	  tricuspid	  regurgitation;	  VE/VCO2	  =	  minute	  ventilation	  to	  carbon	  dioxide	  
production	  ratio;	  VO2	  =	  oxygen	  consumption;	  WU	  =	  Wood	  Units	  
